LY, C., A, A., M, L., H, C., J, Z., O, V. O., . . . S, P. (2026). Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies. Blood. https://doi.org/10.1182/blood.2025030891
Chicago Style (17th ed.) CitationLY, Chen, et al. "Ikaros Degradation by Mezigdomide Reduces T-cell Dysfunction and Improves the Efficacy of Antimyeloma T-cell Therapies." Blood 2026. https://doi.org/10.1182/blood.2025030891.
MLA (9th ed.) CitationLY, Chen, et al. "Ikaros Degradation by Mezigdomide Reduces T-cell Dysfunction and Improves the Efficacy of Antimyeloma T-cell Therapies." Blood, 2026, https://doi.org/10.1182/blood.2025030891.
Warning: These citations may not always be 100% accurate.
